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(A) 
Figure S1. Cont. 
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(B) 
Figure S1. 1H HR-MAS spectra of the 3 different specimens. (A) The averaged NOESY spectrum with 
the corresponding standard deviation calculated for each spectral data point is illustrated for groups 
A, B and C, respectively; (B) Comparison between NOESY and CPMG spectra. One representative 
sample is illustrated respectively for groups A, B and C. As expected, in the CPMG pulse sequence 
the relative peaks intensities vary as compared to the NOESY spectrum. However, peak positions, 
binning regions, and peak behavior along the series of spectra (group A, B, C) do not change. 
Accordingly, PCA of the spectra acquired with the two sequences are identical. 
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Figure S2. Univariate statistical analysis of 1H HR-MAS NMR metabolic profiles. Normalized and 
scaled peak integrals of NMR buckets resulting in significant ANOVA p values (p < 0.05) are 
represented using Box-Whisker plots as in Figure 2. Lac_glyclip: lactate and glycerolipids; 
Creatines.PC: creatines and phosphocholines; X3.33: unknown metabolite at 3.33 ppm; S.inositol: 
Scyllo-inositol; Tau.1: Taurine; P.creatine: phospho-creatine; lip_2.75: lipid at 2.75 ppm; lip_2.23: 
lipid at 2.23 ppm; lip_2.00: lipid at 2.00 ppm. 
 
Int. J. Mol. Sci. 2016, 17, 1814; doi:10.3390/ijms17111814 S4 of S4 
 








Label Description ANOVA 
p Value 





Tumor Oily vs.  
Tumor Calcified 
1 4.36 4.20 glyclip_4.30 glycerolipids 0.790 ns ns ns 
2 4.12 4.08 lac_glyclip lactate, glycerolipids 0.016 0.058 0.018 ns 
3 4.08 4.00 glyclip_4.05 glycerolipids 0.165 ns ns ns 
4 3.92 3.87 creatines-PC 
creatine and 
phosphocreatine 
0.001 0.002 0.003 ns 
5 3.84 3.67 Gly_Glu glycogen, glucose 0.329 ns ns ns 
6 3.53 3.48 Gly glycine 0.887 ns ns ns 
7 3.41 3.35 Tau taurine 0.629 ns ns ns 
8 3.34 3.32 3.33 unknown 0.003 0.005 0.008 ns 
9 3.32 3.29 S-inositol scyllo-inositol 0.000 0.000 0.001 ns 
10 3.26 3.13 Tau taurine 0.001 0.002 0.003 ns 
11 3.20 3.14 cholines 
choline, O-phosphocholine, 
glycero-phosphocholine 
0.823 ns ns ns 
12 3.02 2.99 P-creatine phosphocreatine 0.001 0.003 0.001 ns 
13 2.99 2.98 creatine creatine 0.000 0.000 0.000 ns 
14 2.84 2.69 lip_2.75 =CH–CH2–CH=  0.048 ns ns 0.042 
15 2.45 2.37 Glu-Gln glutamate, glutamine 0.195 ns ns ns 
16 2.26 2.15 lip_2.23 CH2–CH2CO  0.240 0.033 0.080 ns 
17 2.13 2.06 Glu_Gln glutamate, glutamine 0.777 ns ns ns 
18 2.06 1.91 lip_2.00 CH=CH–CH2 0.008 0.008 0.047 ns 
19 1.65 1.48 lip_1.55 CH2–CH2CO 0.393 ns ns ns 
20 1.47 1.41 Ala alanine 0.753 ns ns ns 
21 1.40 1.18 lip_1.30-lac (CH2)n, lactate, threonine 0.690 ns ns ns 
22 1.18 1.11 3-HB 3-hydroxybutyrate 0.728 ns ns ns 
23 0.98 0.79 lip_0.9 CH3-(CH2)n  0.094 ns ns ns 
 
